The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers DOI Creative Commons
Xun Zhang,

Mingpeng Luo,

Jiahang Zhang

et al.

Frontiers in Genetics, Journal Year: 2022, Volume and Issue: 13

Published: Sept. 27, 2022

Systemic therapy is one of the most significant cancer treatments. However, drug resistance often appears and has become primary cause failure. Regulation target, metabolism efflux, cell death escape (apoptosis, autophagy, et al.), epigenetic changes, many other variables are complicatedly involved in mechanisms resistance. In various types cancers, long non-coding RNA H19 (lncRNA H19) been shown to play critical roles tumor development, proliferation, metastasis, multiple as well. The efficacy chemotherapy, endocrine therapy, targeted all influenced by expression H19, especially breast cancer, liver lung colorectal cancer. Here, we summarize relationship between lncRNA tumorigenesis, illustrate caused This review may provide more therapeutic potential targets for future

Language: Английский

Interleukin-6 serves as a critical factor in various cancer progression and therapy DOI
Asma’a H. Mohamed, Abdulrahman T. Ahmed, Waleed Al Abdulmonem

et al.

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(7)

Published: June 20, 2024

Language: Английский

Citations

13
Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy DOI
Weijia Wang,

Behishta Hashimi,

Ping Wang

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

Language: Английский

Citations

1
LncRNA TCL6 regulates miR-876–5p/MYL2 axis to suppress breast cancer progression DOI

Yaobang Liu,

Haipeng Li,

Dahai Chai

et al.

Translational Oncology, Journal Year: 2025, Volume and Issue: 53, P. 102210 - 102210

Published: Jan. 27, 2025

Language: Английский

Citations

1
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine DOI Open Access
Xinming Li, Mingdong Li,

Meiying Huang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 150, P. 113064 - 113064

Published: May 5, 2022

Clinically, cancer drug therapy is still dominated by chemotherapy drugs. Although the emergence of targeted drugs has greatly improved survival rate patients with advanced cancer, resistance always been a difficult problem in clinical treatment. At current level medicine, most cannot escape fate resistance. With and development gene detection, liquid biopsy ctDNA technology, single-cell sequencing molecular mechanism tumor gradually emerged. Drugs can also be updated response to mechanisms bring higher benefits. The use new often leads In this review, multi-molecular are introduced, overcoming discussed from perspective microenvironment.

Language: Английский

Citations

33
The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers DOI Creative Commons
Xun Zhang,

Mingpeng Luo,

Jiahang Zhang

et al.

Frontiers in Genetics, Journal Year: 2022, Volume and Issue: 13

Published: Sept. 27, 2022

Systemic therapy is one of the most significant cancer treatments. However, drug resistance often appears and has become primary cause failure. Regulation target, metabolism efflux, cell death escape (apoptosis, autophagy, et al.), epigenetic changes, many other variables are complicatedly involved in mechanisms resistance. In various types cancers, long non-coding RNA H19 (lncRNA H19) been shown to play critical roles tumor development, proliferation, metastasis, multiple as well. The efficacy chemotherapy, endocrine therapy, targeted all influenced by expression H19, especially breast cancer, liver lung colorectal cancer. Here, we summarize relationship between lncRNA tumorigenesis, illustrate caused This review may provide more therapeutic potential targets for future

Language: Английский

Citations

29